Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI

PHASE2TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2013

Conditions
Chronic Liver DiseaseHepatocellular Carcinoma (HCC)
Interventions
DRUG

13C Sodium Octanoate

13C labeled Sodium Octanoate Substrate is provided in powder form in doses of 100mg for single breath test, and is dissolved in 150cc of tap water before ingestion. Duration of the observation after the drug ingestion is one hour.

Trial Locations (1)

M5G 2N2

Toronto General Hospital, Toronto

Sponsors
All Listed Sponsors
collaborator

Toronto General Hospital

OTHER

collaborator

Medical University of South Carolina

OTHER

collaborator

Northwestern University

OTHER

collaborator

Henry Ford Health System

OTHER

collaborator

Hadassah Medical Organization

OTHER

lead

Meridian Bioscience, Inc.

INDUSTRY